Drug and Therapeutics Committee – Minutes – confirmed

Date / Time	Thursday 10th May 2018 8:15am – 9:30am
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Dr F Umerah, Consultant Anaesthetist Mr R Kapur, Vascular Surgeon Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Prof M Lind, Vice Chair, Professor of Oncology
Apologies	Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Medicines Optimisation Pharmacist, East Riding CCG Dr H Klonin, Consultant Paediatrician

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.05.01	**Apologies**	As above.					
2018.05.02	**Declarations of Interest**	None.					05/18
2018.05.03	**Minutes of the previous meeting**	The minutes were accepted as a true record.					05/18
2018.05.04	**Action Tracker**	**D&T Attendance** WH had amended the spreadsheet and added attendance to HERPC agenda. SPG had emailed Sue Phillips, the lay member. He was informed that Louise Beedle had been asked to send a replacement to cover her illness. This didn't happen, so SPG will reply to ask if Sue Phillips will start attending again or whether he needs to contact Louise Beedle for a new lay member. **D&T Product Requests** TA's without NPR to be highlighted on spreadsheet and circulated at June meeting. **Action tracker – Cancer drugs with NICE Guidance** This related to NICE TA's for cancer drugs, where a D&T application has not been received prior to 31 March 2018. From the tracker, this included atezolizumab, ribociclib, lenvatinib, ceritinib, ibrutinib and ixazomib. POB has discussed this with Sarah Scargill, who has met with Dr V Brown and Dr J Bailey to discuss the way forward. They agreed that the form used to add a new agent to the ARIA e-prescribing system will be updated to include a D&T submission section to speed up	 SPG to reply, to clarify situation. Ongoing - WH to prepare spreadsheet. Action complete. New process to apply to TAs from 01/04/2018.	Actions complete New action: SPG to reply to Sue Phillips Add to agenda for June. POB to bring flow chart and proposal for	 SPG WH POB	 06/18 05/18 06/18	05/18 05/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		the process of new product requests and addition to ARIA.		new form to next D&T			
		WH to review NICE TAs where a NPR form has not been received - ongoing. It is suggested to adopt TAs prior to 01/04/2018 to the formulary, but will still need to provide NHSE with details regarding patient numbers.	WH to draw up a list of outstanding TAs for approval at D&TC.	WH to update collate list of TAs not on formulary	WH	05/18	
		Media Advertising Campaign on Pattie DC informed the committee that currently two advertising banners had been approved with no issues and that he would request feedback on these. Also agreed to give authorisation for another two to be seen trust wide and to seek feedback on these too.	DC to allow 2 more banners to be seen and seek feedback in 3 months.	DC to provide feedback in 3 months	DC	08/18	
		New Product Requests POB had checked about invertase syrup funding. This would be CCG via IFR. As Dr Nair had now left the Trust it was unclear who was doing the IFR request, but AM had already written to Dr Klonin to ask for this to be followed up in Paediatrics.	Action complete.		POB		05/18
		AM had written to applicants and SG had updated the formulary.	Actions complete.		AM		05/18
		Guidelines Systemic Biological therapy for RA was discussed at HERPC.	Action complete.		AG		05/18
		NICE guidance – 12/04/18 meeting Discussion and actions as above. This applies to pertuzumab, daratumumab. POB suggested piloting the new product request/ARIA form with tivozanib and cabozantinib.	See above for actions.				
		NICE Guidance NICE TA513 has been added to formulary next to obinutuzumab.	Action complete.		SG		05/18
		Correspondence Received SG had added to formulary and AM had written to Dr Ming regarding approval of safinamide.	Actions complete.		SG/ AM		05/18
		Chairs Approvals					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		FU had discussed aprotinin with the Clinical Director for Anaesthetics who has not expressed an interest in its use FU agreed to send copy of surgery minutes to POB/SG/AM to confirm this. The committee agreed that if a further chairs approval request was made for aprotinin use "off licence" that it would be refused, but if a reasonable request was made to use it within its current licence that it would be rational to approve it.	Action complete. POB to forward details to FU and AM.		FU POB	 06/18	05/18
2018.05.05	**New Product Requests**	None.					05/18
2018.05.06	**NICE Guidance April/18**	• NG 95 Lyme disease. • NG 96 Care and support of people growing older with learning disabilities. • TA 517 Avelumab for treating metastatic Merkel cell carcinoma. • TA 518 Tocilizumab for treating giant cell arteritis. • TA 519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. • CG 192 Antenatal and postnatal mental health: clinical management and service guidance. • CG 185 Bipolar disorder: assessment and management. • CG 173 Neuropathic pain in adults: pharmacological	All drugs on formulary Noted NPR to be submitted via new process On formulary for Rheumatology On formulary from 11/2017 application for FoC use. These 5 guidelines were all updated to include new safety guidance on valproate use in women and girls of childbearing	No further action No further action ML to seek application No further action No further action Noted - no further action at D&TC.	 ML	 06/18	05/18 05/18 05/18 05/18 05/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		management in non-specialist settings. • CG 137 Epilepsies: diagnosis and management. • CG 90 Depression in adults: recognition and management.	potential.				
2018.05.07	**MHRA Drug Safety Update**	**April 2018** Valproate medicines: contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met. Obeticholic acid: risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment.	Discuss further at MMIG/HERPC. AM to write to Dr Abouda highlighting this risk.	WH to add to agendas AM to write to Dr Abouda	WH AM	06/18 06/18	
2018.05.08	**Minutes from SMPC**	None.					05/18
2018.05.09	**Minutes from HERPC – 31/01/2018**	Noted.					05/18
2018.05.10	**Correspondence received**	None.					05/18
2018.05.11	**Chairs approvals**	Alemtuzumab steroid resistant acute cellular rejection of kidney transplant – Dr M Edey. Oral Tetracycline Capsules - persistent seroma following a mesh repair of an incisional hernia – Mr J Tilsed POB informed the committee that it was no longer possible to procure IV tetracycline but that the pharmacy department had researched the use of oral tetracycline for this procedure. POB will	Noted. Noted.				05/18 05/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		discuss with pharmacy aseptic unit how pharmacy can support this procedure and liaise with Mr Tilsed.					
2018.05.12	**Issues to escalate to OQC**	No issues to escalate.					05/18
2018.05 13	**Any Other Business**	**Glucodrate** SPG informed the committee that Glucodrate had been discontinued by the manufacturer and recommended that St Marks Solution be reinstated on the unlicensed list, as the previously used product. The committee agreed to this. **Sugammadex** POB informed the committee that anaesthetics would be submitting a request to widen the use of sugammadex, as the reversal agent for rocuronium. FU said this was due to an increasing number of patients who would benefit from the use of rocuronium due to its quick onset of action.	WH to add St Marks to unlicensed list & remove Glucodrate from formulary. Noted.	WH to amend both documents	WH	06/18	05/18
2018.05 14	**Date and Time of Next Meeting**	Thursday 14th June 8.15 – 9.30am , Trust Boardroom, HRI.					